Edgewise Therapeutics Inc (EWTX NASDAQ) stock market data APIs
$13.9445
0.14(1%)
as of September 17, 2025
Try our APIs with
free plan!
Edgewise Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Prev. Close
13.9445
Open
14.0875
High
14.3133
Low
13.7519
52 wk Range
10.6-38.12
Market Cap
1 481 M
Shares Outstanding
105 M
EPS
-0.34
Beta
0.265
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Edgewise Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Edgewise Therapeutics Inc data using free add-ons & libraries
Get Edgewise Therapeutics Inc Fundamental Data
Edgewise Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -172 388 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.42
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Edgewise Therapeutics Inc News
New
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic...
Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade
Edgewise Therapeutics, Inc. (EWTX) closed the last trading session at $14.35, gaining 5.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets s...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such i...
Edgewise Therapeutics CSO sells $25,539 in EWTX stock
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Chief Scientific Officer Alan J. Russell, sold 1,907 shares of common stock on August 12, 2025, for approximately $25,539. The shares were sold at an average ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
